Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.

25 Jan 2005Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV.

Administration of irbesartan and/or lipoic acid to patients with the metabolic syndrome improves endothelial function and reduces proinflammatory markers, factors that are implicated in the pathogenesis of atherosclerosis.

Cohort Study
1 effect
4 weeks
58 subjects

Reported Outcomes


Foods rich in Alpha-Lipoic Acid (ALA) Nutrition risk & protective factor
Minor Protective Factor Foods rich in Alpha-Li...

Inflammation Lymphatic outcome
Minor decreased risk of Inflammation
Lymphatic system

Moderate evidence